Prostate cancer (PC) is major common malignancy in males in most industrialized Western countries, where it is the most commonly diagnosed cancer affecting men after middle age (>50 years). Over 90% of PC patients with incurable disease respond to primary treatment,which consists of intervention to lower serum testosterone. However,the duration of response is short (12-33 months) and in almost all patients, is followed by the emergence of a phenotype resistant to androgen deprivation in therapy (known as hormone or androgen-resistant PC). Considerable research efforts have been directed towards the identification of markers associated with the initiation and progression of PC, yet there is little consensus about the target cell within prostate epithelium that is susceptible to malignant transformation. Stem cells may represent a major target for mutations leading to cancer as their longevity assures continued presence during the long latency between carcinogenic agents exposure and cancer development. Therefore in order to allow the development of more effective treatment strategies for PC, a better understanding of the molecular changes that underlie cancer stem cells is required.

Cancer stem cells in prostate adenocarcinoma: a target for new anticancer strategies / Fioriti, Daniela; Mischitelli, Monica; DI MONACO, Franco; DI SILVERIO, Franco; Petrangeli, Elisa; G., Russo; A., Giordano; Pietropaolo, Valeria Antonietta. - In: JOURNAL OF CELLULAR PHYSIOLOGY. - ISSN 0021-9541. - ELETTRONICO. - 216:3(2008), pp. 571-575. [10.1002/jcp.21493]

Cancer stem cells in prostate adenocarcinoma: a target for new anticancer strategies

FIORITI, DANIELA;MISCHITELLI, MONICA;DI MONACO, Franco;DI SILVERIO, Franco;PETRANGELI, Elisa;PIETROPAOLO, Valeria Antonietta
2008

Abstract

Prostate cancer (PC) is major common malignancy in males in most industrialized Western countries, where it is the most commonly diagnosed cancer affecting men after middle age (>50 years). Over 90% of PC patients with incurable disease respond to primary treatment,which consists of intervention to lower serum testosterone. However,the duration of response is short (12-33 months) and in almost all patients, is followed by the emergence of a phenotype resistant to androgen deprivation in therapy (known as hormone or androgen-resistant PC). Considerable research efforts have been directed towards the identification of markers associated with the initiation and progression of PC, yet there is little consensus about the target cell within prostate epithelium that is susceptible to malignant transformation. Stem cells may represent a major target for mutations leading to cancer as their longevity assures continued presence during the long latency between carcinogenic agents exposure and cancer development. Therefore in order to allow the development of more effective treatment strategies for PC, a better understanding of the molecular changes that underlie cancer stem cells is required.
cancer stem cells; prostate cancer
01 Pubblicazione su rivista::01a Articolo in rivista
Cancer stem cells in prostate adenocarcinoma: a target for new anticancer strategies / Fioriti, Daniela; Mischitelli, Monica; DI MONACO, Franco; DI SILVERIO, Franco; Petrangeli, Elisa; G., Russo; A., Giordano; Pietropaolo, Valeria Antonietta. - In: JOURNAL OF CELLULAR PHYSIOLOGY. - ISSN 0021-9541. - ELETTRONICO. - 216:3(2008), pp. 571-575. [10.1002/jcp.21493]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/360601
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact